Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 331

1.

Utility of the RIG-I agonist triphosphate RNA for melanoma therapy.

Helms MW, Jahn-Hofmann K, Gnerlich F, Metz-Weidmann C, Braun M, Dietert G, Scherer P, Grandien K, Theilhaber J, Cao H, Wagenaar TR, Schnurr MM, Endres S, Wiederschain D, Scheidler S, Rothenfußer S, Brunner B, König LM.

Mol Cancer Ther. 2019 Sep 12. pii: molcanther.1262.2018. doi: 10.1158/1535-7163.MCT-18-1262. [Epub ahead of print]

PMID:
31515294
2.

Peritumoural CCL1 and CCL22 expressing cells in hepatocellular carcinomas shape the tumour immune infiltrate.

Wiedemann GM, Röhrle N, Makeschin MC, Fesseler J, Endres S, Mayr D, Anz D.

Pathology. 2019 Aug 21. pii: S0031-3025(19)30328-9. doi: 10.1016/j.pathol.2019.06.001. [Epub ahead of print]

PMID:
31445808
3.

Editorial: Extracellular Enzymes in Aquatic Environments: Exploring the Link Between Genomic Potential and Biogeochemical Consequences.

Sala MM, Piontek J, Endres S, Romani AM, Dyhrman S, Steen AD.

Front Microbiol. 2019 Jun 26;10:1463. doi: 10.3389/fmicb.2019.01463. eCollection 2019. No abstract available.

4.

Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy.

Karches CH, Benmebarek MR, Schmidbauer ML, Kurzay M, Klaus R, Geiger M, Rataj F, Cadilha BL, Lesch S, Heise C, Murr R, Vom Berg J, Jastroch M, Lamp D, Ding J, Duewell P, Niederfellner G, Sustmann C, Endres S, Klein C, Kobold S.

Clin Cancer Res. 2019 Jul 8. doi: 10.1158/1078-0432.CCR-18-3927. [Epub ahead of print]

PMID:
31285373
5.

Advances in cancer immunotherapy 2019 - latest trends.

Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M.

J Exp Clin Cancer Res. 2019 Jun 19;38(1):268. doi: 10.1186/s13046-019-1266-0. Review.

6.

Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy.

Stoiber S, Cadilha BL, Benmebarek MR, Lesch S, Endres S, Kobold S.

Cells. 2019 May 17;8(5). pii: E472. doi: 10.3390/cells8050472. Review.

7.

CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes.

Rapp M, Wintergerst MWM, Kunz WG, Vetter VK, Knott MML, Lisowski D, Haubner S, Moder S, Thaler R, Eiber S, Meyer B, Röhrle N, Piseddu I, Grassmann S, Layritz P, Kühnemuth B, Stutte S, Bourquin C, von Andrian UH, Endres S, Anz D.

J Exp Med. 2019 May 6;216(5):1170-1181. doi: 10.1084/jem.20170277. Epub 2019 Mar 25.

PMID:
30910796
8.

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells.

Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S.

Int J Mol Sci. 2019 Mar 14;20(6). pii: E1283. doi: 10.3390/ijms20061283. Review.

9.

Elliptic flow and R AA of D mesons at FAIR comparing the UrQMD hybrid model and the coarse-graining approach.

Inghirami G, van Hees H, Endres S, Torres-Rincon JM, Bleicher M.

Eur Phys J C Part Fields. 2019;79(1):52. doi: 10.1140/epjc/s10052-019-6537-6. Epub 2019 Jan 21.

10.

Enhancing tumor T cell infiltration to enable cancer immunotherapy.

Zhang J, Endres S, Kobold S.

Immunotherapy. 2019 Feb;11(3):201-213. doi: 10.2217/imt-2018-0111.

PMID:
30730277
11.

CCL1 is a major regulatory T cell attracting factor in human breast cancer.

Kuehnemuth B, Piseddu I, Wiedemann GM, Lauseker M, Kuhn C, Hofmann S, Schmoeckel E, Endres S, Mayr D, Jeschke U, Anz D.

BMC Cancer. 2018 Dec 20;18(1):1278. doi: 10.1186/s12885-018-5117-8.

12.

Microphthalmia-Associated Transcription Factor (MITF) Regulates Immune Cell Migration into Melanoma.

Wiedemann GM, Aithal C, Kraechan A, Heise C, Cadilha BL, Zhang J, Duewell P, Ballotti R, Endres S, Bertolotto C, Kobold S.

Transl Oncol. 2019 Feb;12(2):350-360. doi: 10.1016/j.tranon.2018.10.014. Epub 2018 Nov 28.

13.

Editorial.

Dötsch J, Endres S.

Drug Res (Stuttg). 2018 Nov;68(S 01):S2. doi: 10.1055/a-0731-6178. Epub 2018 Nov 19. German. No abstract available.

PMID:
30453359
14.

High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy.

Rataj F, Jacobi SJ, Stoiber S, Asang F, Ogonek J, Tokarew N, Cadilha BL, van Puijenbroek E, Heise C, Duewell P, Endres S, Klein C, Kobold S.

Br J Cancer. 2019 Jan;120(1):79-87. doi: 10.1038/s41416-018-0341-1. Epub 2018 Nov 15.

PMID:
30429531
15.

Teaching an old dog new tricks: next-generation CAR T cells.

Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S.

Br J Cancer. 2019 Jan;120(1):26-37. doi: 10.1038/s41416-018-0325-1. Epub 2018 Nov 9. Review.

PMID:
30413825
16.

An optogenetic toolbox of LOV-based photosensitizers for light-driven killing of bacteria.

Endres S, Wingen M, Torra J, Ruiz-González R, Polen T, Bosio G, Bitzenhofer NL, Hilgers F, Gensch T, Nonell S, Jaeger KE, Drepper T.

Sci Rep. 2018 Oct 9;8(1):15021. doi: 10.1038/s41598-018-33291-4.

17.

PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.

Rataj F, Kraus FBT, Chaloupka M, Grassmann S, Heise C, Cadilha BL, Duewell P, Endres S, Kobold S.

Front Immunol. 2018 Aug 30;9:1955. doi: 10.3389/fimmu.2018.01955. eCollection 2018.

18.

Generation of a series of Bn fused oligo-naphthalenes (n = 1 to 3) from a B1-polycyclic aromatic hydrocarbon.

Kahan RJ, Crossley DL, Cid J, Radcliffe JE, Woodward AW, Fasano V, Endres S, Whitehead GFS, Ingleson MJ.

Chem Commun (Camb). 2018 Aug 21;54(68):9490-9493. doi: 10.1039/c8cc04701d.

PMID:
30087969
19.

Mechanistic Basis of the Fast Dark Recovery of the Short LOV Protein DsLOV from Dinoroseobacter shibae.

Fettweiss T, Röllen K, Granzin J, Reiners O, Endres S, Drepper T, Willbold D, Jaeger KE, Batra-Safferling R, Krauss U.

Biochemistry. 2018 Aug 14;57(32):4833-4847. doi: 10.1021/acs.biochem.8b00645. Epub 2018 Jul 24.

PMID:
29989797
20.

Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies.

Metzger P, Kirchleitner SV, Koenig LM, Hörth C, Kobold S, Endres S, Schnurr M, Duewell P.

Sci Rep. 2018 Jun 11;8(1):8810. doi: 10.1038/s41598-018-27125-6.

21.

Can we use interleukin-1β blockade for lung cancer treatment?

Gottschlich A, Endres S, Kobold S.

Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S160-S164. doi: 10.21037/tlcr.2018.03.15. No abstract available.

22.

Targeting interleukin-22 for cancer therapy.

Markota A, Endres S, Kobold S.

Hum Vaccin Immunother. 2018;14(8):2012-2015. doi: 10.1080/21645515.2018.1461300. Epub 2018 May 17.

23.

Interaction of 5-hydroxy-l-tryptophan and negative dietary cation-anion difference on calcium homeostasis in multiparous peripartum dairy cows.

Slater CJ, Endres EL, Weaver SR, Cheng AA, Lauber MR, Endres SF, Olstad E, DeBruin A, Crump PM, Block E, Hernandez LL.

J Dairy Sci. 2018 Jun;101(6):5486-5501. doi: 10.3168/jds.2017-13938. Epub 2018 Mar 28.

24.

A modular route to boron doped PAHs by combining borylative cyclisation and electrophilic C-H borylation.

Crossley DL, Kahan RJ, Endres S, Warner AJ, Smith RA, Cid J, Dunsford JJ, Jones JE, Vitorica-Yrezabal I, Ingleson MJ.

Chem Sci. 2017 Dec 1;8(12):7969-7977. doi: 10.1039/c7sc02793a. Epub 2017 Sep 28.

25.

Nlrp3-dependent IL-1β inhibits CD103+ dendritic cell differentiation in the gut.

Mak'Anyengo R, Duewell P, Reichl C, Hörth C, Lehr HA, Fischer S, Clavel T, Denk G, Hohenester S, Kobold S, Endres S, Schnurr M, Bauer C.

JCI Insight. 2018 Mar 8;3(5). pii: 96322. doi: 10.1172/jci.insight.96322.

26.

Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth.

Voigt C, May P, Gottschlich A, Markota A, Wenk D, Gerlach I, Voigt S, Stathopoulos GT, Arendt KAM, Heise C, Rataj F, Janssen KP, Königshoff M, Winter H, Himsl I, Thasler WE, Schnurr M, Rothenfußer S, Endres S, Kobold S.

Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):12994-12999. doi: 10.1073/pnas.1705165114. Epub 2017 Nov 17.

27.

Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.

Mueller I, Ehlert K, Endres S, Pill L, Siebert N, Kietz S, Brock P, Garaventa A, Valteau-Couanet D, Janzek E, Hosten N, Zinke A, Barthlen W, Varol E, Loibner H, Ladenstein R, Lode HN.

MAbs. 2018 Jan;10(1):55-61. doi: 10.1080/19420862.2017.1402997. Epub 2017 Dec 5.

28.

Editorial.

Falkai P, Endres S.

Drug Res (Stuttg). 2017 Nov;67(S 01):S2. doi: 10.1055/s-0043-117517. Epub 2017 Oct 25. German. No abstract available.

29.

Ethnicity, sex, and age are determinants of red blood cell storage and stress hemolysis: results of the REDS-III RBC-Omics study.

Kanias T, Lanteri MC, Page GP, Guo Y, Endres SM, Stone M, Keating S, Mast AE, Cable RG, Triulzi DJ, Kiss JE, Murphy EL, Kleinman S, Busch MP, Gladwin MT.

Blood Adv. 2017 Jun 27;1(15):1132-1141. doi: 10.1182/bloodadvances.2017004820.

30.

Multidate, multisensor remote sensing reveals high density of carbon-rich mountain peatlands in the páramo of Ecuador.

Hribljan JA, Suarez E, Bourgeau-Chavez L, Endres S, Lilleskov EA, Chimbolema S, Wayson C, Serocki E, Chimner RA.

Glob Chang Biol. 2017 Dec;23(12):5412-5425. doi: 10.1111/gcb.13807. Epub 2017 Jul 26.

PMID:
28675672
31.

Inter-annual variability of transparent exopolymer particles in the Arctic Ocean reveals high sensitivity to ecosystem changes.

Engel A, Piontek J, Metfies K, Endres S, Sprong P, Peeken I, Gäbler-Schwarz S, Nöthig EM.

Sci Rep. 2017 Jun 23;7(1):4129. doi: 10.1038/s41598-017-04106-9.

32.

Evaluation of monoacylglycerol lipase as a therapeutic target in a transgenic mouse model of ALS.

Pasquarelli N, Engelskirchen M, Hanselmann J, Endres S, Porazik C, Bayer H, Buck E, Karsak M, Weydt P, Ferger B, Witting A.

Neuropharmacology. 2017 Sep 15;124:157-169. doi: 10.1016/j.neuropharm.2017.03.037. Epub 2017 Mar 31.

PMID:
28373073
33.

Response to Warner Letter.

Endres S, Bogduk N.

Pain Med. 2017 Apr 1;18(4):820-821. doi: 10.1093/pm/pnw254. No abstract available.

PMID:
28034974
34.

50 Jahre Fortschritte in der Arzneimitteltherapie – Rückblick und Ausblick.

Endres S.

Drug Res (Stuttg). 2016 Nov;66(S 01):S4. Epub 2016 Nov 2. German. No abstract available.

PMID:
27806388
Free Article
35.

Acidification and warming affect prominent bacteria in two seasonal phytoplankton bloom mesocosms.

Bergen B, Endres S, Engel A, Zark M, Dittmar T, Sommer U, Jürgens K.

Environ Microbiol. 2016 Dec;18(12):4579-4595. doi: 10.1111/1462-2920.13549. Epub 2016 Oct 24.

PMID:
27690275
36.

Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells.

Wiedemann GM, Knott MM, Vetter VK, Rapp M, Haubner S, Fesseler J, Kühnemuth B, Layritz P, Thaler R, Kruger S, Ormanns S, Mayr D, Endres S, Anz D.

Oncoimmunology. 2016 Apr 25;5(9):e1175794. eCollection 2016.

37.

A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice.

Wiedemann GM, Jacobi SJ, Chaloupka M, Krächan A, Hamm S, Strobl S, Baumgartner R, Rothenfusser S, Duewell P, Endres S, Kobold S.

Oncoimmunology. 2016 May 31;5(7):e1189051. doi: 10.1080/2162402X.2016.1189051. eCollection 2016 Jul.

38.

Effect of fiber insertion depth on antibacterial efficacy of photodynamic therapy against Enterococcus faecalis in rootcanals.

Rödig T, Endres S, Konietschke F, Zimmermann O, Sydow HG, Wiegand A.

Clin Oral Investig. 2017 Jun;21(5):1753-1759. doi: 10.1007/s00784-016-1948-3. Epub 2016 Sep 3.

PMID:
27591860
39.

Interleukin-22 is elevated in lavage from patients with lung cancer and other pulmonary diseases.

Tufman A, Huber RM, Völk S, Aigner F, Edelmann M, Gamarra F, Kiefl R, Kahnert K, Tian F, Boulesteix AL, Endres S, Kobold S.

BMC Cancer. 2016 Jul 7;16:409. doi: 10.1186/s12885-016-2471-2.

40.

The Risks of Continuing or Discontinuing Anticoagulants for Patients Undergoing Common Interventional Pain Procedures.

Endres S, Shufelt A, Bogduk N.

Pain Med. 2017 Mar 1;18(3):403-409. doi: 10.1093/pm/pnw108.

PMID:
27296054
41.

FOXP3+ Cells Recruited by CCL22 into Breast Cancer Correlates with Less Tumor Nodal Infiltration.

Freier CP, Kuhn C, Endres S, Mayr D, Friese K, Jeschke U, Anz D.

Anticancer Res. 2016 Jun;36(6):3139-45.

PMID:
27272839
42.

C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer.

Rapp M, Grassmann S, Chaloupka M, Layritz P, Kruger S, Ormanns S, Rataj F, Janssen KP, Endres S, Anz D, Kobold S.

Oncoimmunology. 2015 Oct 29;5(3):e1105428. eCollection 2016 Mar.

43.

Immunotherapy in Tumors.

Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S.

Dtsch Arztebl Int. 2015 Nov 27;112(48):809-15. doi: 10.3238/arztebl.2015.0809. Review.

44.

Immune response to functionalized mesoporous silica nanoparticles for targeted drug delivery.

Heidegger S, Gössl D, Schmidt A, Niedermayer S, Argyo C, Endres S, Bein T, Bourquin C.

Nanoscale. 2016 Jan 14;8(2):938-48. doi: 10.1039/c5nr06122a.

PMID:
26659601
45.

Mycoplasma hyorhinis-Contaminated Cell Lines Activate Primary Innate Immune Cells via a Protease-Sensitive Factor.

Heidegger S, Jarosch A, Schmickl M, Endres S, Bourquin C, Hotz C.

PLoS One. 2015 Nov 13;10(11):e0142523. doi: 10.1371/journal.pone.0142523. eCollection 2015.

46.

Therapie muskuloskelettaler Erkrankungen--Stand und Perspektiven.

Burmester GR, Endres S.

Drug Res (Stuttg). 2015 Nov;65 Suppl 1:S1. doi: 10.1055/s-0035-1558110. Epub 2015 Nov 4. German. No abstract available.

47.

Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma.

Duewell P, Beller E, Kirchleitner SV, Adunka T, Bourhis H, Siveke J, Mayr D, Kobold S, Endres S, Schnurr M.

Oncoimmunology. 2015 Apr 14;4(10):e1029698. eCollection 2015 Oct.

48.

Suppression of intratumoral CCL22 by type i interferon inhibits migration of regulatory T cells and blocks cancer progression.

Anz D, Rapp M, Eiber S, Koelzer VH, Thaler R, Haubner S, Knott M, Nagel S, Golic M, Wiedemann GM, Bauernfeind F, Wurzenberger C, Hornung V, Scholz C, Mayr D, Rothenfusser S, Endres S, Bourquin C.

Cancer Res. 2015 Nov 1;75(21):4483-93. doi: 10.1158/0008-5472.CAN-14-3499. Epub 2015 Oct 2.

49.

TLR and RLR Signaling Are Reprogrammed in Opposite Directions after Detection of Viral Infection.

Hotz C, Roetzer LC, Huber T, Sailer A, Oberson A, Treinies M, Heidegger S, Herbst T, Endres S, Bourquin C.

J Immunol. 2015 Nov 1;195(9):4387-95. doi: 10.4049/jimmunol.1500079. Epub 2015 Sep 21.

50.

Synthesis of cyclic diborenes with unprecedented cis-configuration.

Bissinger P, Braunschweig H, Celik MA, Claes C, Dewhurst RD, Endres S, Kelch H, Kramer T, Krummenacher I, Schneider C.

Chem Commun (Camb). 2015 Nov 14;51(88):15917-20. doi: 10.1039/c5cc07103h. Epub 2015 Sep 11.

PMID:
26360103

Supplemental Content

Loading ...
Support Center